Bone cements: development of partially degradable ionomer cements by Gomes, Filipa Oliveira
Filipa Oliveira Gomes 
Setembro de 2011 
Universidade do Minho
Escola de Ciências
U
M
in
ho
|2
01
1
 F
ili
pa
 O
liv
ei
ra
 G
om
es
 
 Bone Cements – development of partially
 degradable ionomer cements. 
 B
on
e 
C
em
en
ts
 –
 d
ev
el
op
m
en
t o
f p
ar
tia
lly
 d
eg
ra
da
bl
e 
io
no
m
er
 c
em
en
ts
. 
Filipa Oliveira Gomes 
Setembro de 2011 
Universidade do Minho
Escola de Ciências
Trabalho realizado sob a orientação de:
Supervisor: Professor Doutor Rui Luís Gonçalves dos Reis 
Co-supervisor: Doutor Ricardo Alexandre Rodrigues Pires 
Orientador do Departamento de Química: Doutora Maria 
Isabel Pontes Correia Neves 
Dissertação em Técnicas de Caracterização e Análise Química 
Nome: Filipa Oliveira Gomes 
Endereço eletrónico: figs8@hotmail.com 
Telefone: 914192367  
Número do Bilhete de Identidade: 13249166 
O título da tese: “Bone Cements – development of partially degradable ionomer 
cements.” 
Orientadores 
Supervisor: Professor Doutor Rui Luís Gonçalves dos Reis 
Co-supervisor: Doutor Ricardo Alexandre Rodrigues Pires  
Orientador do Departamento de Química: Doutora Maria Isabel Pontes Correia 
Neves 
Mestrado em Técnicas de Caracterização e Análise Química  
 
 
É AUTORIZADA A REPRODUÇÃO PARCIAL DESTA TESE  APENAS PARA EFEITOS DE 
INVESTIGAÇÃO, MEDIANTE DECLARAÇÃO ESCRITA DO INTERESSADO, QUE A TAL SE  
COMPROMETE. 
 
Universidade do Minho, 29-09-2011 
 
Assinatura:  
iii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Quero dedicar a minha tese a duas pessoas muito importantes para mim: à minha 
mãe que passou momentos muito complicados durante o meu Mestrado e que 
continuou a lutar devido à sua força e à minha madrinha que foi o meu pilar a 
todos os níveis principalmente a nível emocional, sem este pilar tudo seria muito 
complicado.” 
iv 
 
Acknowledgments 
 
Gostaria de agradecer ao Professor Rui Reis por me ter dado a oportunidade de 
desenvolver a minha tese de mestrado no centro de excelência em biomateriais, 
biodegradáveis e biomiméticos (3B’s). Agradeço também a disponibilidade 
demonstrada e as ideias/opiniões sugeridas ao longo da tese. É muito gratificante 
trabalhar num grupo com um nível tão elevado de conhecimento e com pessoas de 
diferentes nacionalidades e áreas. 
Agradeço também ao Doutor Ricardo Pires pelo planeamento do trabalho e pelo apoio 
nas várias etapas. É gratificante encontrar uma pessoa com humildade, alegria e 
vontade de trabalhar e ajudar como o Doutor Ricardo Pires. Muito obrigada pela 
compreensão e pela motivação, foi uma das pessoas mais importantes ao longo deste 
trabalho. 
Gostaria de agradecer à minha orientadora da Universidade do Minho, a Professora 
Isabel Neves, pela sua disponibilidade e conhecimento sobre esta área de estudo. 
Decidi fazer a minha tese na área dos materiais devido ao incentivo e entusiasmo que 
a Professora Isabel Neves demonstrou. 
Agradeço à Doutora Elsa Ribeiro pela ajuda nas análises de SEM e EDS e pela 
discussão dos resultados obtidos e também ao Doutor Stanislav Ferdov pela ajuda nas 
análises de XRD.  
Quero deixar o meu agradecimento ao grupo dos 3B’s em geral e especialmente a 
algumas pessoas que me marcaram pela discussão de temas relacionados com a 
minha área e também sobre outros assuntos mas sobretudo pela amizade.  
Agradeço particularmente à Maria que dispensou muito do seu tempo para me ensinar 
e pela preocupação demonstrada sobre o meu trabalho. 
Aos meus colegas e professores de Mestrado, muito obrigada pela amizade e pelo 
conhecimento que adquiri. 
Um agradecimento especial a toda a minha família principalmente ao meu pai por toda 
a força e inteligência que demonstrou no decorrer do meu trabalho. Mesmo com todas 
as adversidades nunca demonstraste fraqueza, obrigada pela força pai! Quero 
agradecer ao meu irmão o facto de sempre poder contar com ele, apesar de estar a 
viver em França. 
As pessoas que mencionei contribuíram de forma diferente para o meu trabalho mas 
todas juntas foram essenciais para o resultado final. 
v 
 
Abstract 
The first glass-ionomer cement (GIC) was developed by Wilson and Kent in 
1971. GICs are usually prepared through the mixing of a fluoroaluminosilicate glass 
powder, polyacrylic acid (PAA) and water. The PAA attacks the glass particles that 
leach some of its cations (e.g. Al3+ and Ca2+) to the cement matrix. These cations 
cross-link the PAA chains yielding the final cement structure. GICs possess as main 
advantage the ability to bind to hydroxyapatite present in the dentin and bone. These 
systems have been mainly used in the dentistry field (non-systemic application). 
Applications that induce a systemic uptake of the cement components (e.g. bone 
cements) have been discarded due to the presence of aluminium (a known neurotoxin) 
on the GIC formulations. 
The present thesis targets the development of new glass-ionomer cement (GIC) 
formulations with potential to be applied as bone cements. To this purpose, new 
aluminium-free glass compositions of general formula 0.340SiO2 : 0.300ZnO : (0.250-x-
y)CaO : xSrO : yMgO: 0.050Na2O : 0.060P2O5 (where x and y = 0.000 or 0.125) were 
synthesised and tested in the formulation of GICs through their mixing with PAA and 
water. The different parameters that influence the GIC mechanical performance (e.g. 
glass particle size, molecular weight of PAA, proportion of the constituents, etc.) were 
optimized. The GIC prepared with the developed glass compositions where in vitro 
tested for their bioactivity. To this purpose, GIC samples were immersion in SBF and 
their ability to form a surface apatite layer was evaluated by: 1) determination of the 
concentration of the calcium and phosphorous in the SBF (executed by ICP); 2) 
quantification of the calcium and phosphorous present at the surface of the cements 
(executed by EDS) and 3) morphological analysis (executed by SEM). Micro-CT was 
also used to evaluate the spatial distribution of the polymeric and inorganic phases. 
Finally, in an attempt to enhance the GIC biodegradability it was incorporated starch in 
the cement formulations, at different weight percentages (5% and 25%). 
The results obtained under this thesis proved the suitability of some of the developed 
glass compositions (e.g. 0.34SiO2: 0.30ZnO: 0.125CaO: 0.125SrO: 0.05Na2O: 
0.06P2O5) to prepare GICs in accordance with its use as bone cements, including: 
suitable mechanical performance (compressive strength, CS=25 MPa; compressive 
modulus, CM=492 MPa) for non-load bearing applications; bioactivity; and 35 % 
porosity. Moreover, after the 8th week of degradation under enzymatic medium it was 
detected reducing sugars in the degradation solutions of the starch-containing 
formulations confirming its biodegradation potential at a longer timeframe. 
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Resumo 
O primeiro cimento de ionómero de vidro (GIC) foi desenvolvido por Wilson e 
Kent em 1971. Estes cimentos são normalmente preparados através de uma mistura 
de um pó de vidro geralmente fluoroaluminosilicatos com ácido poliacrilico (PAA) e 
água. O PAA ataca as partículas de vidro que liberta alguns dos seus catiões (e.g. Al3+ 
e Ca2+) para a matriz do cimento que vão ligar-se às cadeias do PAA. Os cimentos 
possuem como vantagens a capacidade para se ligarem à hidroxiapatite presente nos 
dentes e ossos. Estes sistemas têm sido usados principalmente na área dentária 
(aplicações não sistémicas). Aplicações que induzem uma absorção sistémica dos 
componentes do cimento têm sido rejeitadas devido à presença de alumínio (uma 
neurotoxina conhecida). 
 A presente tese tem como principal objetivo o desenvolvimento de novas 
formulações de cimentos de ionómero de vidro para aplicação como cimentos ósseos. 
Para este propósito, foram sintetizadas novas composições de vidros sem alumínio 
com a fórmula geral 0.340SiO2: 0.300ZnO: (0.250-x-y)CaO: xSrO: yMgO: 0.050Na2O: 
0.060P2O5 (onde x e y = 0.000 ou 0.125) e utilizadas na formulação de cimentos 
através da mistura com PAA e água. Os parâmetros que influenciam a performance 
mecânica dos cimentos (e.g. tamanho de partícula, peso molecular do PAA, proporção 
dos constituintes, etc.) foram otimizados. Os cimentos foram analisados in vitro para 
obter informação acerca da sua bioactividade. Para este estudo, amostras de cimentos 
foram imersas em SBF e a sua capacidade de formar uma superfície de apatite foi 
avaliada através da: 1) determinação da concentração de cálcio e fósforo presente em 
SBF (efetuado por ICP); 2) quantificação de cálcio e fósforo presente na superfície dos 
cimentos (efetuado por EDS); 3) análise morfológica (efetuado por SEM). Micro-CT foi 
utilizado para avaliar a distribuição de fases poliméricas e inorgânicas. Finalmente, 
para obtenção de cimentos biodegradáveis foi incorporado amido na sua formulação, 
com diferentes percentagens (5% e 25%). 
Os resultados obtidos nesta tese demonstraram a possibilidade de algumas 
composições de vidro (e.g. 0.340SiO2: 0.300ZnO: 0.125CaO: 0.125SrO: 0.050Na2O: 
0.060P2O5) contribuírem para a preparação de cimentos com interesse para aplicação 
como cimentos ósseos, incluindo uma adequada performance mecânica (Compressive 
strength, CS= 25 MPa; Compressive modulus, CM= 492 MPa) para zonas de carga 
não permanente, bioactividade e 35 % de porosidade. Além disso, após a oitava 
semana de degradação em condições enzimáticas foram detetados açúcares 
redutores nas formulações contendo amido confirmando o seu potencial de 
biodegradação. 
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1. General remarks 
This thesis addresses developments and optimizations on glass-ionomer 
cements (GICs) targeting their application in the repair of bone. Under this 
perspective, this introductory chapter will comprise an initial section that 
includes a series of considerations on the bone tissue, namely, its structure, 
properties, repair steps and self-regeneration. Afterwards, it will be presented a 
section on the biomaterials relevant to the bone regeneration and repair, 
namely, the inorganic-based bone cements - the group of materials that present 
properties and characteristics more similar to the system under study. This 
section also includes relevant concepts in the biomedical field, such as, 
biodegradability and bioactivity. Finally, a third section will focus on the GIC 
system, its components, curing reactions, properties, applications, advantages 
and disadvantages. 
2. Bone regeneration/treatment 
2.1 Bone – What is it? 
Bone is one of the main constituents of the skeleton that acts as a 
support structure for the vertebrates. In the materials point of view, it has been 
considered as a heterogeneous bioceramic composite exhibiting variations on 
its chemical composition in between species. In fact the most noted differences 
in its mineral constitution are observed between two types of bones: rat and fish 
bone. It was also detected differentiated chemical composition in the skeletons 
of the hamster, monkey, pig, man and other vertebrates [1-5]. 
In order to better understand the relationships between bone chemical 
composition and its properties it is relevant to understand the mechanisms 
involved in bone related chemical processes, e.g. chemistry of calcification, 
bone as an ion reservoir, among others. Biltz and co-workers also concluded 
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that bone possesses chemical differences that are dependent on the age, 
exerted strength, metabolic activity and sex of the individual. Depending on 
these factors, it is observed a variation on the quantity of water and organic 
components present in the bone. In this perspective, it was also established a 
relationship between the bone water content and its degree of mineralization 
[3]. 
Each individual presents different types of bone within the body. The main 
differences are related with its density, from a more compact structure (cortical 
bone) to a less dense material (cancellous bone). Based in the study of the 
bone individual components it was concluded that its main properties (stiffness, 
elasticity, hardness and toughness) are derived from their combination in an 
heterogeneous structure [1]. It is also known that systematic loading affects 
bone mass and size. This is one of the reasons for the observed variations on 
bone density with the age of the individual [5]. 
2.2 Constitution of bone 
Bone is a metabolically active tissue composed by a mineral and an organic 
phase that contribute to two thirds and one third of its weight, respectively [4]. 
As shown in Figure 1 the bone exhibits a structure that has elements of several 
length scales and which, together, perform various mechanical, chemical and 
biological functions, e.g. it acts as a support structure, reservoir of mineral ions, 
among others [6] 
 
Figure 1: Hierarchical structural organization of bone. 
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Has stated before, bone is a heterogeneous bioceramic that combines an 
inorganic with an organic phase. In terms of its chemical composition, its main 
component is in the inorganic phase: carbonated hydroxyapatite (60-70 % w/w) 
of low crystallinity. The organic phase is mainly composed by fibrils of Type I 
collagen, although, other components are present, namely: growth factors and 
glycosaminoglycans. Finally, approximately 10 % of bone is composed by water 
[2]. 
The different types of bones (e.g. cortical or cancellous) are histologically 
different, although, their chemical composition is similar. Cortical bone 
represents, approximately, 80 % of the skeleton. It is dense and compact and 
possesses a high resistance to bending. Most of this type of bone is calcified 
and its main function is mechanical support and protection. Cancellous bone 
represents 20 % of skeletal mass and, approximately, 80% is found at the ends 
of long bones and in the interior of the vertebrae and pelvis. It is less dense, 
more elastic, and has a higher turnover rate than compact bone [7]. 
Bone is also constituted by cells. In fact there are three main types of cells in 
the bone tissue: osteoblasts, osteocytes and osteoclasts. Osteoblasts are the 
cells responsible for synthesis and deposition of minerals and, therefore, the 
mineralization of bone extracellular matrix. During their activity osteoblasts can 
become isolated in a cavity surrounded by bone matrix as a result of the 
deposition of minerals. Under these circumstances they differentiate into 
osteocytes, one of the most abundant types of cell in bone. Finally, osteoclasts 
are responsible for the bone remodelling process and their principal function is 
to resorb mineralized bone [8]. 
2.3 Mechanical properties of bone 
In the context of mechanical evaluation it is relevant to describe the 
different data that can be extracted from the uniaxial mechanical tests. In this 
perspective, Figure 2 presents a stress-strain curve obtained from a mechanical 
test. The curve is the result of applied stress and the following data can be 
collected [1]: 
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• Beginning of the elastic behaviour; 
• Elastic range; 
• Range of plastic deformation; 
• Breaking point; 
• Amount of energy absorbed by the material; 
• Elastic modulus (measuring the slope at the elastic range).  
 
 
Figure 2: Stages of mechanical deformation: the elastic range (E), the continuum 
damage mechanics range (CDM) and the fracture mechanics (FM). 
The mechanical behaviour of a material can be divided in three phases (I, II and 
III). Under I (the elastic regime) the material deforms reversibly and only 
residual damage occurs. Phase II corresponds to the plastic regime where the 
material absorbs enough energy to develop microcracks. In phase III it occur 
mechanical failure and the amount of energy that the material is able to absorb 
reduces drastically. 
Under mechanical loading, the bone can suffer of different types of ageing that 
can lead to fractures. These ageing mechanisms can be derived from creep 
(with prolonged load) or fatigue (repetitive) [9]. It has become recently clear that 
bone and other biological hard tissues show weak interlamellar interfaces, 
which are able to absorb energy and/or divert a crack. In this way, bone has a 
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limited capacity to detain the onset and growth of fracture. Furthermore, it is 
now increasingly clear that initiation of cracks in biomineralized tissues is far 
less important than their propagation since biological tissues use a number of 
processes (e.g. crack diversion/deflection, fibre pull-out, crack and/or matrix 
bridging) to increase the required amount of energy for fracture to occur [9]. 
The mechanical behaviour of bone depends on its type (cortical or cancellous). 
Additionally, as with any biological sample its variability is significant 
representing a reasonably large interval of expectable values. Table 1 resumes 
the most relevant mechanical properties of the two main types of bone. 
 
Table 1: Mechanical properties of cortical and cancellous bone [10]. 
Property Cortical bone Cancellous bone 
Compressive strength (MPa) 100-230 2-12 
Flexural, tensile strength (MPa) 50-150 10-20 
Strain to failure (%) 1-3 5-7 
Young’s (tensile) modulus (GPa) 7-30 0.5-0.05 
 
2.4 Bone repair 
When the ends of fractured bone are held in place, there are two types of 
primary mineralized tissue healing that can occur: gap repair and contact repair. 
In gap repair, healing begins by the formation of blood vessels and connective 
tissue fills the empty spaces. After 2 weeks osteoblasts fill the gaps in the tissue 
by secreting osteoid. Upon 10 more days osteoids became mineralized and the 
osteoblasts that remained in the matrix become entrapped. The new bone acts 
as a scaffold for remodelling promoted by osteoclasts and osteoblasts. In 
contact repair, there is no gap between the bone ends, although, necrotic bone 
must be removed before new bone can be deposited to repair the fracture. 
Osteoclasts are responsible to resorb the necrotic bone. Afterwards, 
osteoblasts attach to the tissue matrix, creating a ruffled cell border between the 
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cell and the bone surface promoting mineralization of the bone and subsequent 
re-linking of the bone surfaces. 
In bone repair, secondary healing occurs when bones are not rigidly supported 
after the injury. The first step is to create an ECM-rich bridge to support the 
fracture and the unstabilized mineralized tissue will undergo secondary repair. 
Most compact bone surfaces that make up the outer layer are covered by 
osteoblasts that promote mineralization. The wound site will re-gain some 
mechanical strength after 4 days of healing (Figure 3 (a)). 
 
 
 
(a) (b) 
Figure 3: (a) Primary and secondary mineralized tissue repair; (b) Primary and 
secondary bone remodelling. 
The mineralized bone remodelling is a dynamic process and occurs throughout 
the life of the individual. It produces new bone to be able to handle the demands 
of mechanical stresses. Primary gap remodelling also occurs during the repair 
process and lamellar bone (that presents collagen in a lamellar structure) is 
used as scaffold. After ca. 4 weeks osteogenesis stops leaving behind a 
vascularized cavity called an osteon that runs parallel to the long axis. A greater 
ultimate strength is obtained when a more osteons cross the injury site. 
In primary gap healing, remodeling is important for restoring tissue strength. 
However, in primary contact healing, remodeling is coupled to the repair 
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process. During contact remodeling, the cutting cones mature, depositing 
lamellar bone centripetally to form ring-shaped structures. 
The remodelling can last until 6 months and the healed bone is similar to the 
non-injured tissue in terms of robustness, although, it appears less organized. 
In this step it is also required to remove the excess of callus produced during 
the bone repair, being this step one of the main differences between the two 
reparation processes: primary and secondary. This callus removal is executed 
by the osteoclasts (Figure 3 (b)) [11]. 
 
2.5 Self-regeneration of bone 
Bone is a dynamic tissue that is being formed and resorbed in a 
continuous cycle. These activities are executed in response to hormonal and 
physical factors. Bone is able to regenerate under different circumstances, e.g. 
when a fracture occurs in the bone. Unfortunately, this ability for self-
regeneration is limited when the size of the trauma is too large. These cases 
are known as critical size defects due to the inability of the bone to self-
regenerate. In order to repair these defects it is mandatory to execute a bone 
replacement. This can be achieved using a series of different biomaterials [12]. 
3. Biomaterials relevant to bone regeneration/repair 
A biomaterial is a synthetic or natural material used to: replace part of 
living tissue; or to restore a specific function of the living tissue. From this 
definition it is clear to understand that the development of biomaterials usually 
comprise different fields of knowledge (Table 2), from materials science, biology 
and medicine. The effective influence of these areas is dependent on the 
specific tissue that is targeted and the function that the biomaterial is required to 
execute. In Table 3 is shown the application areas of the biomaterials. These 
can range from assistance in the diagnostic and treatment of diseases to tissue 
replacement or correction and improvement of tissue function [13]. 
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Table 2: Fields of knowledge relevant for the development of biomaterials [13]. 
Knowledge domain Examples 
Materials science 
and engineering 
Structure-property relationship of synthetic and biological 
materials including metals, ceramics, polymers, 
composites, tissues (blood and connective tissues), etc. 
Biology and 
physiology 
Cell and molecular biology, anatomy, animal and human 
physiology, histopathology; experimental surgery, 
immunology, etc 
Clinical sciences All the clinical specialties: dentistry, maxillofacial, 
neurosurgery, obstetrics and gynecology, ophthalmology, 
orthopaedics, otolaryngology, plastic and reconstructive 
surgery, thoracic and cardiovascular surgery, veterinary 
medicine, and surgery, etc. 
 
Table 3: Different areas where the use of biomaterials has been exploited [13]. 
Area of intervention Examples 
Replacement of diseased or damaged 
part 
Artificial hip joint, kidney dialysis 
machine 
Assist in healing Sutures, bones plates, and screws 
Improve function Cardiac pacemaker, intraocular lens 
Correct functional abnormality Cardiac pacemaker 
Correct cosmetic problem Augmentation mammoplasty, chin 
augmentation 
Aid to diagnosis Probes and catheters 
Aid to treatment Catheters, drains 
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The specific biological responses that the different biomaterials promote when 
in contact with the cells and body fluids are an important factor to be considered 
when designing new biomaterials [14-16]. In fact, the biomaterial-cell interaction 
is governed by the biomaterial surface and composition. Moreover, the different 
biomaterial properties (e.g. mechanical, biocompatibility, etc.) are governing 
their application area. 
Table 4: Different types of biomaterials [13]. 
Biomaterial Advantages Disadvantages Examples 
Polymers (nylon, silicone 
rubber, polyester, 
poytetrafuoroethylene, 
etc.) 
Resilient 
Easy to 
fabricate 
Not strong 
Deforms with 
time, may 
degrade 
Sutures, blood 
vessels, hip 
socket, ear, nose, 
other soft tissues, 
sutures 
Metals (Ti and its alloys, 
Co-Cr alloys, stainless 
steels, Au, Ag, Pt, etc.) 
Strong, tough, 
ductile 
May corrode, 
dense, difficult 
to make 
Joint 
replacements, 
bone plates and 
screws, dental root 
implants, pacer 
and sutures wires 
Ceramics (aluminium 
oxide, calcium 
phosphates including 
hydroxyapatite, carbon) 
Very 
biocompatible, 
inert, strong in 
compression 
Brittle, not 
resilient, difficult 
to make 
Dental; femoral 
head of hip 
replacement, 
coating of dental 
and orthopaedic 
implants 
Composites (carbon-
carbon, fibre-reinforced 
bone cement) 
Strong, tailor-
made 
Difficult to make Joint implants, 
heart valves 
 
As can be seen from Table 4, in general, biomaterials can be produced from a 
variety of different materials (e.g. polymers, metals, ceramics and composites), 
although, their selection is dependent on their specific properties. As an 
example, while ceramics, metals and composites are usually used to repair 
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tissues that require high mechanical modulus, polymers that present lower 
mechanical modulus are usually selected to develop biomaterials for the repair 
or substitution of soft tissue. In the following subsection it will be presented 
examples of ceramic-based biomaterials due to the fact that is the type of 
biomaterials that presents more similarities with the systems studied under this 
thesis (GICs). 
3.1 Ceramic-based biomaterials 
Calcium phosphate cements (CPCs) were introduced in the field of 
bioceramics more than two decades ago and represented a real change in the 
medical applications. The possibility to have an injectable material with 
mouldable behaviour represented benefits for several clinical applications, e.g. 
minicracks, maxillofacial deformities and defects, vertebroplasty, among many 
others. 
The formation of CPCs is based on the combination of one or more calcium 
orthophosphates. These phosphates are mixed with the liquid phase forming a 
paste that is able to set and harden after being implanted within the body. The 
CPC setting occurs through dissolution and precipitation of its components 
throughout the curing reactions. Its hardening is based on the entanglement of 
the precipitated crystalline phases. The most stable crystalline phases formed 
during the CPC curing are hydroxyapatite and brushite at pH >4.2 and pH<4.2, 
respectively [17]. 
The understanding of the mechanism of interaction of CPCs, allows accessing 
their long-term potential. It has been shown the occurrence of a gradual 
modification at the ceramic surface due to dissolution, precipitation and ion-
exchange reactions. These events results in the production of a carbonate-
containing, calcium-deficient hydroxyapatite with small crystal sizes. These 
changes are the beginning of a series of events that promotes bioactivity and 
that induces parallel reactions in cellular activity, bone mineralization and 
organic matrix deposition. 
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Absorption of proteins and other biological molecules occurs and the 
surrounding cells attach to the CPC surface. All these phenomena lead to the 
gradual incorporation of the ceramic into the regenerated bone tissue. Calcium 
phosphate ceramics include several materials which differ not only in their 
chemical composition, but also in their specific surface area, macro- and 
microporosity and crystal structure. There are differences due to variations in 
the calcium to phosphate ratio; as examples, tricalcium phosphate, 
hydroxyapatite and tetracalcium phosphate have Ca/P ratios of 1.50, 1.67 and 
2.00 respectively, and there are other materials with ratios in between these 
(Table 5). Furthermore, hydroxyl ions may be missing from the structure, as in 
oxyhydroxyapatite, and other trace ions may be present. The importance of 
these compositional variations is not merely academic but they affect the 
biological response [18]. 
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Table 5: The main calcium phosphates used in the biomedical field [8]. 
Compounds Chemical Formula (Ca/P) Molar 
Ratio 
Abbreviation 
Precipitated CaP 
Dicalcium phosphate CaHPO4 1.00 DCP 
Monocalcium 
phosphate 
monohydrate 
Ca(HPO4)2.H2O 0.50 MCPM 
Dicalcium phosphate 
dihydrate (Brushite) 
Ca(HPO4)2.2H2O 1.00 DCPD 
Octacalcium 
phosphate 
Ca8H2(PO4)6.5H2O 1.33 OCP 
Precipitated 
hydroxypatite 
(tricalcium phosphate) 
Ca10-x(HPO4)x(PO4)6-
x(OH)2-x0≤x≤2 
1.50-1.67 PHA 
Amorphous calcium 
phosphate 
Ca3(PO4)2.nH2O 
n = 3-4.5; 15-20 % 
H2O 
1.50 ACP 
High-Temperature CaP 
Monocalcium 
phosphate 
Ca(HPO4)2 0.50 MCP 
α-Tricalcium 
phosphate 
α-Ca3(HPO4)2 1.50 α-TCP 
β-Tricalcium 
phosphate 
β-Ca3(PO4)2 1.50 β-TCP 
Sintered hydroxypatite Ca5(PO4)3OH 1.67 HA 
Oxyapatite Ca10(PO4)6O 1.67 OXA 
Tetracalcium 
phosphate 
Ca4(PO4)2O 2.00 TetCP 
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Different types of bone cements are available for filling bone defects originated 
by illness or traumatic accident. More recently, bone cements have been tested 
for tendon-bone healing. In this perspective, Osteocrete, a magnesium-based 
injectable bone cement, has been reported to possess tensile strength 3 times 
higher than the calcium-based CPCs in both tendon-bone attachments and 
bone-bone structures. It has also been shown to enhance the formation of bone 
callous in an osteotomy model when compared with CPCs. While these 
preliminary studies are encouraging, the ability of Osteocrete to improve the 
healing of the bone tissue has not been studied [19]. 
Synthetic hydroxyapatite is a calcium-phosphate bioceramic of general 
chemical formula Ca10(PO4)6(OH)2. It has been tested in the development of 
different types of biomaterials mainly targeting the substitution/regeneration of 
bone. This approach follows a biomimetic path derived from the fact that 
hydroxyapatite is one of the main constituents of natural bone. In fact, the 
inclusion of hydroxyapatite in biomaterials usually enhances their bioactivity and 
biocompatibility [20-23].The advances in the ceramic technology generated a 
significant number of ceramic materials for medical purposes. As an example, 
tricalcium phosphate (TCP) was first proposed in 1920 as a bioresorbable 
substance to fill bone defects. However, TCP is a weak ceramic, unable to 
sustain significant loading. The need for tougher and stronger ceramics was not 
met before 1965, when the fillers alumina-based materials were proposed for 
the substitution of hip joints. Zirconia and synthetic calcium phosphate ceramics 
(together with other calcium and/or phosphorus containing ceramics and 
glasses) were then proposed as alternatives to alumina and TCP, respectively. 
After roughly 100 years of clinical use, we come to the conclusion that there is, 
so far, no ceramic biomaterial able to create a strong and biologically relevant 
interface with bone. On the other hand, ceramics and glasses are able to 
promote direct bone-implant adhesion without soft tissue interlayer, although, 
their mechanical properties are not sufficient to allow their use in load-bearing 
applications [24]. 
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3.2 Biocompatibility and bioactivity 
Biocompatibility is defined as the ability of a material has to give an 
appropriate response to a specific application (this definition was established by 
consensus among the specialists in the field of biomaterials, in a conference in 
Chester, UK. Williams 1987). Inevitably the introduction of a new material in the 
human body produces a specific response that depends on the composition of 
the biomaterial, shape, size, geometry and aspects of the organism/patient such 
as age, immunological sensitivity, health, local implant, among others. 
Therefore, it is difficult to mention what are the parameters that should be 
accounted to evaluate the biocompatibility of a specific material. Under this 
perspective each biomaterial should be evaluated according to the roles that it 
was designed to execute [25]. 
The bioactivity of a material is related with his ability to produce a chemical or 
biological response from the surrounding medium in order to promote tissue 
regeneration. A typical in vitro bioactivity test evaluates the ability of the 
biomaterial to form an apatite surface layer when in contact with simulated body 
fluid (SBF), a solution that presents the ionic concentrations similar to human 
blood plasma. The higher the ability of the biomaterial to form an apatite layer 
the higher is its bioactive potential [26]. As an example bioglass was the first 
successful glass to present bioactivity. It was first reported by Hench and co-
workers in 1970s and was used clinically. The main application of these glasses 
is for replacement of the damaged tissue, as for example, treatment of facial 
bone injuries or benign bone tumours [27, 28]. 
3.3 The relevance of biodegradability 
Biodegradable biomaterials are used in reconstructive surgery when the 
body itself has the capacity to self-regenerate the damaged tissue. Usually, a 
biomaterial to be used under this approach needs to present bioactivity and to 
promote tissue growth/regeneration. Upon application, the biomaterial start the 
degrade allowing the surrounding tissue to grow to the intervened area. The 
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correct matching between its degradation rate and the tissue 
growth/regeneration allows a complete regeneration of the damaged tissue 
upon full degradation of the biomaterial. Under this perspective it is of critical 
importance the non-toxicity of the degradation products. The first synthesized 
biodegradable biomaterial approved to be used in clinical applications (e.g. 
sutures) was the poly(glycolic acid) (PGA). With the progress of tissue 
engineering other biodegradable materials were developed (e.g. gellan gum, 
etc.) [29, 30]. The biodegradable biomaterials can be applied in the biomedical 
field in a diversified manner. In Table 6 it is presented examples of the targeted 
applications of biomedical devices produced using biodegradable biomaterials 
[8]. 
Table 6: Applications of biodegradable biomaterials in biomedical devices. 
Application Biomedical device 
Adhesion and fixation of 
tissues 
Suture, bone fixation material and adhesive 
Support and reinforcement Suture reinforcement material 
Temporary substitutes for 
tissues 
Substitute material for endocranium 
Shape maintenance and 
isolation 
Membrane for prevention of tissue adhesion 
Securing space for tissue 
regeneration 
Guided tissue regeneration, guided bone 
regeneration 
Scaffold for tissue 
regeneration 
Skin, cartilage, bone, blood vessel 
 
A common approach to impart biodegradability to different biomaterials is the 
addition of starch. This methodology has been attempted in the development of 
bone cements [31, 32]. Starch is a glucose-based polymer created by the 
combination of two structures: amylose and amylopectin (Figure 4). 
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Figure 4: Structure of starch (amylose and amylopectin) [33].  
 
Amylose is an essentially linear structure where the glucose units are joined by 
α(1→4) glycosidic linkages. Amylopectin consists of linear α(1→4) linked 
glucose chains including branched positions with α(1→6) linkages every 24 to 
30 glucose residues, on average [8]. 
One of the main advantages of including biodegradable starch in the 
formulation of biomaterials is the presence of α-amylase in the Human body that 
is specific for starch components. Additionally, its degradation products are not 
toxic and metabolized by the body. 
4. Glass-ionomer cements (GICs) 
4.1 The development of GICs 
Wilson and Kent created the first conventional GICs combining a glass 
powder from the system SiO2-Al2O3-CaO-CaF2 with PAA, as a result of their 
pioneering work at the Laboratory of the Government Chemist, London, in the 
early 1970s [34-49]. The studied glasses became vulnerable to acid attack and 
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established a strong link with the acidic PAA [40]. Initial application of these 
GICs was in dentistry, as a colour matched alternatives to amalgam restoratives 
due to two main advantages: strong adhesion to dentin and ability to prevent 
caries in tooth structures [34, 50-52]. Research work during the following 
decades addressed their main disadvantages, namely, sensitivity to moisture 
during initial hardening; poor mechanical properties, among others [53]. 
Different optimizations introduced in the following decades resulted in the 
development of conventional GIC formulations that present enhanced 
mechanical performance, tuned curing time and reduced sensitivity to moisture. 
More significant modifications were promoted with the addition of UV-curable 
resins in the cement matrix. These resin-modified GICs present mechanical 
properties that overpass most of the conventional GICs, although, their anti-
cariogenic potential was significantly reduced. In this sense, their properties, 
ease of moulding and ease of application, still makes conventional GIC as an 
extremely versatile solution for cementing a series of different biomaterials. 
4.2 The importance of glass composition 
The glass powder present in GIC formulations is usually composed by 
calcium fluoroaluminosilicates. This component has two main functions: 1) to 
act as a source of cations essential for the evolution of the cement curing 
reactions; and 2) to reinforce the final cement structure. 
Within the typical glass systems used in GIC formulations it is possible to 
distinguish glass formers (e.g. SiO2), glass modifiers (Ca2+) and components 
with intermediate behaviour (e.g. Al2O3). The selection of components to be 
used in the glass formulation is dependent on several factors, including their 
influence in: the glass mechanical properties; the glass reactivity; and, most 
important, the glass basicity. In fact, the GIC curing is governed by acid-base 
reactions between an acidic polymer and a basic glass. In this sense, it is 
mandatory that the glass structure presents significant basicity. This basicity is 
usually conferred by the modifier cations. 
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4.3 Methodologies to synthesize the glass component 
4.3.1 Melt-quenching methodology 
Melt-quenching methodology is a high temperature process that involves 
the melting of the whole glass formulation and its subsequent fast decrease of 
temperature below the glass transition (Tg). This procedure induces the 
formation of the short to medium range order that is characteristic of glasses. 
The timeframe of the temperature reduction is so short that it does not allow the 
formation of long-range structural ordering. In general, glasses produced by this 
methodology present higher stability when compared with other glass 
preparation methods, e.g. sol-gel. Additionally, melt-quenched glasses usually 
promote the improvement of the mechanical behaviour of GIC compositions 
[14]. 
One of the main drawbacks of the melt-quenching technique is the fact that not 
all the compositions produce a melt. Depending on the glass compositions the 
melting temperature of the formulation is, in some cases, difficult to achieve with 
laboratory furnaces. Additionally, in the quenching step it is important to reach 
the appropriate temperature decrease rate that is also dependent on the 
composition. This should be fast enough to limit nucleation and to inhibit 
crystallization of the structure, although, nucleation and crystallization rates are 
also dependent on the composition. In fact, some formulations present a very 
high nucleation and crystallization rate and the production of pure glass phases 
is difficult. In these cases the melt quenching methodology generates crystalline 
phases within the glass phase, i.e. glass-ceramics. 
4.3.2 Sol-gel methodology 
The sol-gel methodology is based on the hydrolysis and condensation of 
the glass former precursors (e.g. silicon and aluminium alkoxides, etc.) 
solubilised in specific solvents (e.g. water, ethanol, etc.). It also involves the 
addition of nitrates or chlorides of the glass modifiers (e.g. calcium nitrate, etc.) 
to the processing solution and the use of specific catalytic and/or initiator 
conditions (e.g. ammonium hydroxide, etc.). This approach presents a series of 
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advantages compared to the melt-quenching approach, namely: a better 
compositional control; morphological control (e.g. particles, fibers, membranes, 
etc.); lower processing temperatures; among others [54]. 
The main reactions occurring during the sol-gel methodology are the hydrolysis 
of the glass precursors and their subsequent condensation. For the first step to 
occur it is essential the presence of an hydrolyzing medium (e.g. water) in order 
to produce the hydroxides/acids of the glass formers (e.g. silicic acid, aluminium 
hydroxide, etc.). The condensation reaction (second step) occurs between the 
different hydroxides/acids with the release of water molecules. This step is 
usually catalysed by different compounds, e.g. ammonium hydroxide, nitric acid, 
etc. [55]. Depending on the targeted morphology, the methodology can include 
an additional step usually designated as gelation. In this step the colloidal 
solution of particles is aged allowing their condensation into a macroscopic 
system (Figure 5) [14]. 
 
Figure 5: Sol-gel process (https://www.llnl.gov/str/May05/Satcher.html). 
The whole sol-gel methodology is performed at lower temperatures than the 
melt-quenching approach. This characteristic imparts the valuable advantage of 
enabling the preparation of glasses incorporating bioactive compounds (e.g. 
proteins, drugs, etc.) sensitive to high temperatures [56, 57]. Moreover, glasses 
produced by this methodology usually present higher specific surface area and 
bioactivity [58]. 
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4.4 The polymeric component 
 The GICs curing reactions only occurs if the polymeric component 
present significant acidity. Throughout the development and optimization of GIC 
different polymers have been tested in the formulations. As examples, can be 
pointed out PAA, poly (acrylic acid-co-itaconic acid) and poly (acrylic-co-maleic 
acid) with structural formulas presented in Figure 6 [59]. 
 
Poly(acrylic acid) 
 
 
Poly(acrylic acid-co-itaconic acid) Poly(acrylic-co-maleic acid) 
Figure 6: Polymers already tested in the development of GIC formulations. 
From all the polymeric components tested until today PAA continues to be the 
most used in GIC formulations. This is essentially due to its high acidity, 
availability and lower price when compared to the other tested polymers [59]. 
The PAA molecular weight (Mw) directly influences cement mechanical 
behaviour and the cement paste initial viscosity. GIC mechanical performance 
is enhanced with PAA of high Mw, although, their high viscosity limits the 
homogeneity and mixability of the cement pastes. In this perspective, it is 
important to obtain a compromise between these two properties. The optimal 
formulations are prepared with polymeric components that have the highest Mw 
without significantly affecting the viscosity of the cement paste [60-63]. 
4.5 GIC curing reactions 
GICs are formed when an acid-base reaction occurs between the glass 
powder and an aqueous solution of PAA, creating an inorganic-organic 
interlinked structure. The curing mechanism is composed by two general steps, 
gelation (Figure 7) and maturation. 
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Figure 7: GICs curing reactions during the gelation stage [64]. 
During gelation, hydrated protons from the PAA/H2O penetrate the surface of 
the glass particles and attack its basic sites (i.e. cations such as Na+, Ca2+, 
octahedral Al3+, etc.). The cations from the surface layer are leached to the 
cement matrix, promoting the ionic cross-linking of the PAA chains, through 
their carboxylate anions. This step usually occurs under a timeframe of 
approximately, 30 min. During the maturation step the tetrahedral aluminium 
present in the glass particle surface layer is leached under the same type of 
PAA acid attack. The longer timeframe of this maturation step (approximately, 
24h) is attributed to the higher stability of the tetrahedral aluminium that is 
covalently bounded within the glass structure [34, 41, 50, 65-70]. 
4.6 Properties, applications and importance of GICs and its 
constituents 
4.6.1 Properties of GICs 
There are a series of advantages on using GIC as cementation agent of 
different dental restorations, namely: chemical adhesion to tooth; anti-cariogenic 
effect; mechanical behaviour under compression loading; among others. The 
GIC chemical adhesion to the tooth is due to the dentin chemical structure. This 
is one of the main advantages of the GICs and is based on formation of ionic 
cross-links between the PAA carboxylate anions and the Ca2+ from the dentin’s 
hydroxyapatite [71]. Their anti-cariogenic effect is mainly related with the use of 
fluorine in the glass compositions. Fluorine is gradually leached from GIC to the 
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surrounding dentin strengthening the tooth resistance to bacterial proliferation 
[44, 72]. Moreover, it has been proven that GICs are able to act as a fluorine 
reservoir. In this sense GICs are not only leaching fluorine to the surrounding 
tissue but is also able to uptake additional fluorine from the surroundings (e.g. 
toothpastes) [73]. In relation to the mechanical behaviour, Kenny et al reported 
that it depends on the molecular weight (Mw) of PAA [74]. Additionally, the 
powder to liquid ratio [75], concentration of PAA and the use of chelating agents 
also influences the final performance of the GICs. In general, the available 
formulations achieve compressive strengths up to 200 MPa and biaxial flexural 
strengths up to 50 MPa. The ratio of “bound” and “unbounded” water is a 
determinant factor affecting the GIC properties. In fact, the highest is the 
proportion of “unbounded” water the lower is the mechanical performance and 
the GIC general stability. Finally, the glass particle size also influences 
significantly the mechanical behaviour of the GICs and the cement curing 
reactions. The lower the glass particle size, the higher is its surface area and 
lower is the GIC crack deflection [76]. The main drawback of the reduction of 
the particle size is related with the faster setting kinetics. This variation reduces 
the time available to the medical doctor to manipulate the cement paste and to 
apply it at the intervention site. In this sense, it is always desirable to obtain a 
compromise between glass particle size, mechanical properties and GIC setting 
kinetics to develop optimized formulations. 
A number of modifications can be made in the formulations to enhance the GIC 
properties, namely: (1) alternative polymers, as the polyacid component; (2) 
dried polymers blended with the glass and activation by the addition of water; 
(3) ceramic-metal hybrid cements; (4) metal-reinforced cement for enhanced 
mechanical properties; (5) resin-modified GICs (RMGICs) using initiators and 
resins capable of undergoing photochemical polymerization [35, 77]. 
GICs have demonstrated to possess biocompatibility and bioactivity. These 
cements are able to release osteoconductive ions such as calcium and fluoride  
to the surrounding tissue [65]. The incorporation of strontium in the glass 
formulations has been done for several years due to its characteristic 
properties, namely: radiopacifier, antibacterial properties and can help in the 
regeneration of healthy bone. In fact, it has been proven that low doses of 
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strontium (300 mg Kg-1 day-1 of Sr2+ for 9 weeks) can stimulate bone formation 
and inhibit bone resorption in both animal and humans. Strontium has an affinity 
for bone being incorporated by surface exchange and ionic substitution [78]. 
4.6.2 Applications of GICs 
GICs have been tested in the cementation of different biomaterials 
dedicated to the repair or substitution of tooth and bone. Its main application 
area continues to be the dentistry field, where conventional GICs are used to 
cement different types of composites used to repair teeth or as temporary filler 
before the application of a definitive dental restoration. Non-conventional GICs, 
such as the RMGICs have been additionally proposed as definitive dental 
restorations [44, 79-81]. 
Hurrell-Gillingham and co-workers suggest that the main properties of GICs 
(including adhesion to mineralized tissues, minimal exotherm during setting and 
good biocompatibility) enables them to be exploited in the otology field [82]. 
Although, the most relevant and underexploited application of GIC remains to 
be in the orthopaedic field as bone cements [74]. 
4.6.3 Biocompatibility of GICs 
GICs are not bioinert but should be classified as bioactive. Hatton and 
co-workers tested a set of GICs under in vitro cell culture and they 
demonstrated that some GICs are biocompatibility. Although, other studies 
proved that the ions present in GICs namely aluminium and fluoride are 
responsible for the toxicicity of some formulations. These studies also report a 
relation between the toxicity of the formulations and the ionic concentrations 
and culture conditions [83]. 
4.6.4 The importance of GIC cations in the regeneration of tissue 
The GICs have been tested in vivo with encouraging results. The 
formation of bone was observed in some formulations after 6 weeks of 
implantation and being stable during 1 year. In addition, in the short term there 
is an inflammatory response observed in soft tissues adjacent to the GIC. The 
tissue reaction was caused by one or both of the following factors: 
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(i) Reduction of tissue pH due to the acidic PAA. This is the most probable 
cause of tissue necrosis (a damage of the surrounding tissues). 
(ii) Release of free glass particles from the cement to the surrounding tissues. 
This is probably induced by the excess of water originated on the surrounding 
tissue that migrates to the GIC affecting its curing reactions and promoting the 
release of glass particles. Glass particles are known to cause inflammatory 
response in adjacent soft tissues. In surgery (e.g. dentistry), it is important to 
avoid excess of the moisture contamination during placement of the GICs. 
A limited dose of ion release is the significant factor that determines tissue 
response to regeneration. In contrast, as previously mentioned, high levels of 
ionic leaching from the GIC can produce inflammatory response. Upon GIC 
application it is expectable an initial time period where inflammation occurs in 
the surrounding tissue due to higher levels of ionic and PAA leaching from the 
GIC. After this initial timeframe the inflammatory response is suppressed and 
the GIC appears with a layer of relatively mature bone tissue. At this stage the 
osteoconductive potential of the GIC is evident (a property not common in other 
types of bone cements) [83]. 
a) Aluminium and its toxicity 
Aluminium in the ionic form (Al3+) has several implications in human 
health and its toxicity has been studied by several authors. This cation is 
responsible for many degenerative diseases including Alzheimer’s and 
Parkinson’s. Boyce and co-workers reported that encephalopathy and 
osteomalacia was detected in patients being subject to dialysis. It was observed 
that the water used in the dialysis contained high levels of aluminium. Bone 
biopsies detected the presence of high levels of aluminium in the bone, 
confirming that the origin of the detected pathologies was the aluminium present 
in the water used for the dialysis [84]. 
Another case study (a bone reconstruction of a woman with 52 years old) was 
reported by Reusche et al. This reconstruction was performed with a GIC 
prepared by mixing a calcium aluminium fluorosilicate glass and an aqueous 
solution of polycarboxylic acid. This GIC (Ionocem) contained high levels of 
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aluminium and six weeks after implantation the patient presented a fatal 
aluminium encephalopathy (see Figure 8) [85]. 
 
Figure 8: Aluminium inflammatory response of Al-based GICs resulting in an irregular 
density at the specific positions (arrowheads) [85]. 
In general, it has been accepted that the release of aluminium present in the 
GICs formulations, used as bone cements, produces a deleterious effect in the 
health of the intervened patients [85]. Although, this has been considered a 
critical component of the glass compositions used to prepare GICs. In fact, it 
has been proposed that Al3+ has a critical role in the formation of the PAA 
carboxylate cross-links within the GIC cement matrix [86]. Under this 
perspective, Boyd and co-workers tested several aluminium-free glass 
compositions and their cement forming ability. Under these studies the same 
authors found that glass compositions where aluminium was substituted by zinc 
are able to produce GIC. The developed formulations presented properties that 
are consistent with their application in orthopaedic procedures, according to 
ISO5833 [78, 87]. 
b) Other relevant cations 
There are a series of other cations that possess a relevant role in the 
setting chemistry and final properties of the GICs. As stated before, zinc has 
demonstrated that it is able to substitute aluminium in the glass compositions 
used to prepare GICs. Although not completely proven, it is reported that zinc 
imparted other relevant properties to the final GICs, namely: bactericidal and 
bioactivity.  Zinc is also an essential trace element which presents effects on in 
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vitro and in vivo bone formation and bone protein synthesis. It promotes the 
proliferation of osteoblasts and many biological functions. It promotes new bone 
formation in the surroundings of the implants [88]. Additionally, zinc deficiency 
may be a risk factor in the pathogenesis of osteoporosis [89]. 
Their bivalency makes the cations derived from the elements of the second 
group of the periodic table, namely, magnesium, calcium and strontium, suitable 
to act as PAA ionic cross-linkers. In fact, calcium has been described as the 
second most relevant cations in the GIC setting chemistry [90]. It has been 
reported in the glass composition since the initial development of the GICs. Its 
role is similar to aluminium in the cross-linking of the PAA network through 
calcium-carboxylate ionic linkages. Due to their similar characteristic, 
magnesium and strontium have an equivalent potential. In contrast, beryllium 
and barium are usually not included due to their toxicity. 
The nature of strontium and its biological function has not been investigated as 
extensively as the role of calcium and magnesium of the same chemical family. 
Strontium is believed to have a participation in dental tissue mineralization due 
to their properties similar to those presented by calcium. Its antibacterial effect 
has been claimed but remains to be clarified: previous in vitro work on 
commercial RMGIC (Fuji II LC) showed that strontium was not cytotoxic when in 
contact with human osteoblastic cells. Strontium, as a substitute of calcium in 
hydroxyapatite, has been studied recently and claimed to prevent bone 
fractures [90]. In addition, strontium may inhibit osteoclastic turnover and 
promote the osteoblastic one. Moreover, bone strength increases and the risk of 
fractures decrease [91, 92]. It has been also reported to contribute to the 
increase in bone mass and volume when given at low doses, re-mineralizing 
skeletal lesions. It seems that strontium directly suppresses bone resorption 
and has no deleterious effect on bone mineralization. Strontium has also 
reported to have beneficial effects on bone formation in rodents and humans 
which results in increased trabecular volume. It has been also confirmed that 
strontium increases the bone strength and in bone density due to its higher 
atomic weight in comparison with calcium. Strontium is currently used as dopant 
of the crystalline structures of calcium salts to improve their biological 
properties. The successful incorporation of strontium ions in the composition of 
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hydroxyapatite, calcium phosphate cements and calcium silicates help on the 
proliferation and activity of osteoblastic cells [58]. Finally, Johnson et al. studied 
the effect of the incorporation of strontium in GICs. They reported a relation 
between the presence of strontium in the GIC and a marked reduction of bone 
ash; increase in the amount of magnesium and potassium in the bone; and by 
depressed calcium contents as compared to normal bone [93]. 
Drouet et al. studied the effect of strontium and magnesium in the formation of 
apatites. They observed that the magnesium taken up was found to be 
reversibly fixed to the apatite structure independently of their maturation stage. 
In contrast, the amount of reversibly fixed strontium decreased noticeably with 
maturation in a strontium-containing solution. These findings suggested that 
magnesium remained mostly on the surface of nanocrystalline apatites whereas 
strontium was progressively incorporated into the growing apatite domains [94]. 
Magnesium is a cation that presents high physiological interests in the 
biomedical field. It is essential to human metabolism and is naturally present in 
the bone. It may actually have stimulatory effects on the growth of new bone 
and it is classified as an essential element for the human body [88]. 
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This chapter compiles the information relative to the materials used during the 
experimental procedures, and the methodologies employed in the synthesis and 
characterization of the developed GICs. 
1. Materials 
The safety information, purity and supplier of the chemicals used for the glass 
synthesis and in the formulation of the cements are presented in Table 1. Each 
reagent was used at specific proportions to prepare glasses of different 
compositions. The addition of corn starch to the cement formulation was tested in 
an attempt to improve its biodegradability. α-Amylase was used as a degradation 
catalyser in the starch-containing formulations. 
 
Table 1: Specifications of all reagents used for the glass and cement preparation. 
 
Reagent Supplier Purity Hazard 
Codes 
Symbol 
Sodium Hydrogen carbonate 
(NaHCO3) 
Riedel de-
Haen 
99.70 % Not 
Hazardous 
- 
Calcium carbonate (CaCO3) Sigma 99 % Xi 
 
Magnesium oxide (MgO) Sigma 98 % ND - 
Diammonium hydrogen 
phosphate (NH4)2HPO4 
Sigma 98.00 % Xi 
 
Zinc oxide (ZnO) Sigma nd ND - 
Strontium carbonate (SrCO3) Sigma 98 % ND - 
Silica (SiO2) Merck nd T 
 
Polyacrylic acid (Mw=50kDa) Sigma nd ND - 
Polyacrylic acid (Mw=450kDa) Sigma nd T 
 
Polyacrylic acid 
(Mw=1250kDa) 
Sigma nd ND - 
Corn starch Sigma nd Not 
Hazardous 
- 
α-amylase Sigma nd Xn 
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2. Materials synthesis and processing  
2.1 Glass synthesis 
Glass formulations were prepared by mixing the appropriate quantities of the 
glass precursors in a mortar using ethanol as a mixing adjuvant. The final glass 
compositions are detailed in Table 2. 
Table 2: Composition of the synthesized glass formulations. 
Component G1* G2 G3 G4 G5 G6 
SiO2 (SiO2) 0.340 0.340 0.340 0.340 0.340 0.340 
ZnO (ZnO) 0.300 0.300 0.300 0.300 0.300 0.300 
MgO (MgO) 0.250 - - 0.125 - 0.125 
CaO (CaCO3) - 0.250 - 0.125 0.125 - 
SrO (SrCO3) - - 0.250 - 0.125 0.125 
Na2O (NaHCO3) 0.050 0.050 0.050 0.050 0.050 0.050 
P2O5 ((NH4)2HPO4) 0.060 0.060 0.060 0.060 0.060 0.060 
 * Glass composition G1 did not melt at the experimental conditions used under this work. In this 
perspective G1 composition was not used to prepare GICs. 
 
Upon mixing, the formulations were dried overnight in a vacuum oven at 35 ºC [1-
3]. The dried formulations were heated in a crucible to 300 ºC for 30 minutes to 
release the ammonia from the diammonium hydrogen phosphate; 650 ºC for 30 
minutes to allow the release of carbon dioxide from the carbonates; and 1300 ºC 
to allow the complete melting of the mixture [4, 5]. The melted mixtures were 
splat quenched by pouring the melt onto a metal plate maintained at room 
temperature (Figure 1) [6-13]. 
 
Figure 1: Illustration the melt quenching process. 
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The glass blocks were frozen with liquid nitrogen and grounded with a pestle and 
mortar (Figure 2). Upon size reduction the glass particles were separated by 
sizes using an Analytical Sieve Shaker (Retsch AS200) for 5 min at a rate of 60 
rpm. With this methodology it was possible to collect the glass fractions that 
presented particle sizes of x<63 µm, 63 µm<x<125 µm and 125 µm<x<250 µm. 
Figure 2: Glass powder preparation and sieving. 
2.2 Cement preparation 
Cement formulations were prepared by mixing the glass powder with PAA and 
water at appropriate amounts (55: 21: 24 by mass). After mixing, the cement 
pastes were introduced into a Teflon mould to produce cylindrical cement 
specimens of 6 mm diameter and 11 mm height (Figure 3). 
 
 
Figure 3: Example of the preparation of a moulded cement formulation. 
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The cement formulation that presented higher mechanical resistance was 
modified in an attempt to enhance its biodegradability. For this purpose it was 
added corn starch to the formulation (5 and 25 % by weight) [14]. 
3. Characterization methodologies 
3.1 Mechanical performance under compression loading 
All the developed cements were mechanically evaluated under compression 
loading. For each formulation it was prepared six cylindrical specimens (as 
detailed in the cement preparation section). The mechanical loading was 
executed on an Instron 5540 (Instron, USA) equipped with a load cell of 1 kN and 
2 mm/min of crosshead speed (Figure 4). In all cases, the samples were 
maintained at room temperature for 24 hours prior to the mechanical testing [15]. 
From the stress-strain curves it was determined the compression modulus (CM) 
and the compressive strength (CS). The compression modulus was determined 
as the initial slope (elastic regime) of the stress-strain curves. 
 
 
Figure 4: Instron 5540, Universal mechanical testing machine. 
The CS was calculated from equation 1: 
 
Equation 1 
Position of 
the cement 
specimen 
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where, CS is the compressive strength (MPa), ρ is the maximum applied load (N) 
and d is the diameter of the sample (mm) [11, 16, 17]. 
 
3.2 Fourier Transform Infrared spectroscopy 
The evolution of the acid-base reaction between the glass particles and the PAA 
was followed by Fourier Transform Infrared (FTIR) spectroscopy. The FTIR 
spectra were acquired on KBr pellets. For this purpose, 400 mg of KBr (Sigma-
Aldrich, >99 % trace metals basis) was mixed with 2-4 mg of sample in a mortar 
and pestle until forming an homogeneous mixture (Figure 5). This mixture was 
moulded to a pellet using a press (Pike, USA). The FTIR spectra were acquired 
on a Shimadzu IR-Prestige 21 spectrometer, under transmittance mode using a 
resolution of 4 cm-1, a range between 4400-400 cm-1 and 32 scans. 
 
 
Figure 5: Preparation of the KBr pellets. 
 
3.3 X-ray powder Diffraction 
The crystalline/amorphous state of the synthesised glasses was evaluated using 
X-ray powder diffraction (XRD) [18]. The diffractograms were collected on a 
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Bruker D8 Discover, operating with CuK radiation, in  θ/2θ mode, between 6º and 
70º, with a step increment of 0.04º and an acquisition time of 1s per step. 
3.4 Scanning Electron Microscopy 
Scanning Electron Microscopy (SEM) was used to analyze the formation and 
morphology of calcium phosphate layers (in vitro bioactivity) at the surface of the 
cements after immersion in SBF at 7 and 14 days (non-immersed samples were 
used as controls). The micrographs were collected on a Leica Cambridge S360 
microscope using a beam energy of 15.0 kV and a working distance (WD) of 19 
mm. All the analysed samples were previously coated with gold to enhance its 
conductivity (Figure 6). 
 
Figure 6: Gold deposition, microscope chamber and overall view of SEM microscope. 
 
3.5 Micro-Computed Tomography 
The cements samples were analysed by micro-Computed Tomography (micro-
CT) in order to determine the polymer, glass and pore spatial distribution and 
volume percentages. The collection of images was performed in a micro-CT 
Skyscan 1072 (Skyscan, Belgium) operating with a voltage of 104 kV and with a 
current of 96 µA (Figure 7). Upon image acquisition the noise was reduced using 
nRecon software. Afterwards, 200 sliced images were obtained using the CT-An 
program. These images were used to produce a 3D reconstructions with the 
same program (CT-An). Manipulating the image with a threshold of 40 to 80 for 
the glass and 80 to 140 for the polymer it was possible to separate the 
contribution of PAA and glass components to the cement volume, as well as the 
free pore volume [19]. 
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Figure 7: Micro-Computed Tomography equipment. 
 
3.6 Water uptake and weigh loss 
3.6.1 Water uptake 
Cement samples (prepared 24 h before testing to allow stabilization) were 
immersed in Phosphate Buffer Saline (PBS) solution at a ratio of 1:15 (sample 
mass : PBS volume) and inserted in a shaking water bath maintained at 37 ºC 
and 60 rpm. In all the cases it was prepared three replicas of each sample that 
were collected during the study. Cement samples were collected at various time 
points (1, 2, 4, 8 and 12 weeks) and were washed with distilled water. The 
excess of water present in the surface of the cements was dried with paper and 
then the cements were immediately weighted. 
The water uptake (WU) was calculated using the following equation [20]: 
 
Equation 2 
where, mtp is the mass of the wet specimen at a specific time point and mf is the 
mass of cement after drying at 37 ºC to constant weight. 
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3.6.2 Weight loss 
The weight loss (WL) was calculated during the water uptake (WU) tests. In the 
WL case, the cements were removed from the PBS solution at the same time 
intervals as the ones used for the WU (1, 2, 4, 8 and 12 weeks) and were dried in 
the oven, at 37 ºC, until constant weight. The percentage of WL was calculated 
using the following equation: 
 
Equation 3 
where, mf is the mass of the dried cement after its immersion in PBS and mi is 
the mass of the dried cement before immersion in PBS. 
 
4. Bioactivity assays 
4.1 Preparation of Simulated Body Fluid and the cements 
samples 
Simulated body fluid (SBF) is a solution that mimics the ion concentrations in the 
human plasma, as indicated in Table 3. 
Table 3: Ionic concentration of the human blood plasma and the SBF solution. 
Ions Concentration in Blood plasma 
(mM) 
Concentration in SBF solution 
(mM) 
Na+ 142.0 142.0 
K+ 5.0 5.0 
Mg2+ 1.5 1.5 
Ca2+ 2.5 2.5 
Cl- 103.0 147.8 
HCO3- 27.0 4.2 
HPO43- 1.0 1.0 
SO42- 0.5 0.5 
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The preparation of SBF followed a specific protocol as detailed in the following 
steps:  
• 1 L of distilled water was maintained in a bath at the temperature of 100 
ºC-150 ºC and at 300-450 rpm; 
• It was performed a temperature and pH control; 
• The masses of each reagent was added in the order described in Table 4 
to produce 2 L of SBF; 
• The temperature of the solution was adjusted to 36.5 ºC and the pH to 
7.40; 
• The solution was transferred to a volumetric flask and the volume was 
adjusted when the temperature reached 20 ºC; 
• After sterilization by filtration, the solution was stored at 5-10 ºC. 
 
Table 4: Quantities and sequence of the addition of each reagent in the protocol 
followed for the preparation of the SBF solution. 
Sequence Reagent Quantity  Purity /% 
1 NaCl 16.072 g 99.5 
2 NaHCO3 0.704 g 99.5 
3 KCl 0.450 g 99.5 
4 K2HPO4.3H2O 0.460 g 99.0 
5 MgCl2.6H2O 0.622 g 98.0 
6 HCl 1M 50 mL - 
7 CaCl2 0.586 g 95.0 
8 Na2SO4 0.144 g 99.0 
9 TRIS 12.236 g 99.0 
10 HCl 1M 25 mL - 
 
4.2 Bioactivity assay  
Cement samples (prepared 24 h before testing to allow stabilization) were 
immersed in Simulated Body Fluid (SBF) solution at a ratio of 1:10 (sample mass 
: SBF volume) and inserted into an oven maintained at 37 ºC. Cement samples 
(including three replicas per formulation and time point) were collected at two 
time points (7 and 14 days). The collected SBF solutions were filtered and stored 
in a controlled temperature room at 4 ºC until further analysis. 
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4.3 Analysis of calcium and phosphorous concentration by 
inductive coupled plasma – optical emission spectroscopy 
Inductive coupled plasma optical emission spectrometry (ICP-OES) was used to 
determine the calcium and phosphorous concentrations in the SBF solution 
before and after the immersion of the developed cements at 7 and 14 weeks 
(Figure 8). The higher ability of the cement to form a calcium phosphate layer in 
the surface of the cement (a measure of its in vitro bioactivity), higher is the 
reduction of the calcium and phosphorous concentrations in the SBF. The 
analytical methodology comprises the nebulisation of the SBF solutions into an 
oven maintained at a temperature between 6000 and 10000 K to atomize the 
chemical compounds. Afterwards, the samples’ absorption at specific 
wavelengths (λ=422.67 nm for Ca and λ=213.62 nm for P) was measured and 
the Ca and P concentrations were determined using calibration curves previously 
obtained with standard solutions (Alfa Aesar). 
 
Figure 8: ICP-OES analysis of the developed cements. 
 
4.4 Energy-dispersive X-ray spectroscopy 
The Energy-dispersive X-ray Spectroscopy (EDS) was used to analyse the 
surface elemental composition of the prepared cement samples before and after 
immersion in simulated body fluid (SBF) – bioactivity assays. For this purpose, a 
Link eXL-II Oxford spectroscope was used at an energy of 7.0 KeV. The EDS 
analysis was used to quantify the calcium and phosphorous present in the 
surface of the cements after immersion during 7 and 14 days in SBF. Prior to the 
analysis the samples were carbon coated to improve their conductivity (Figure 9). 
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Figure 9: Carbon deposition of the analysed samples and EDS equipment. 
 
5. Degradation studies 
The kinetics and percentage of cement degradation are important parameters to 
evaluate their suitability as bone cements. In fact, it is expectable that the 
developed cements will be slowly reabsorbed and excreted from the body. The 
kinetics of this process should match the formation of new bone so that the loss 
of the cementing effect of the reabsorbed part will not impart a reduction of 
properties in the intervened portion of the bone. In this perspective, it was 
analysed the kinetics and percentages of weight loss of the developed cements 
(see water uptake and weight loss in section 3 of this chapter). Additionally, the 
degradation kinetics of the cements prepared with the addition of starch particles 
were analysed in the presence of a starch-specific enzyme, α-amylase. 
5.1 Enzymatic degradation – reducing sugars 
The degradation of the starch-containing cements was tested in the presence of 
a starch-specific enzyme, α-amylase. This enzyme is known to hydrolyse the α-
1,4-glycosidic linkages of polysaccharides (e.g. starch) to monosaccharides, 
such as, maltose and dextrins (scheme 1). 
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Cement degradation was promoted by immersion of specimens in an enzyme 
containing solution (150 U/L) for different time periods, 0, 1, 2, 4, 8, and 12 
weeks. At the specific time points, the solutions were analysed for the presence 
of reducing sugars. Their concentration was determined by the dinitrosalicylic 
acid (DNS) method. The 3,5-dinitrosalicylic acid is converted to 3-amino-5-
nitrosalicylic acid in alkaline conditions according to the reaction 1. 
 
OH
OH
NO2O2N
O OH
OH
NH2O2N
O
NaOH
 
 
Reaction 1 
This last compound (3-amino-5-nitrosalicylic acid) forms a complex with the 
reducing sugars, which presents an absorption peak at 540 nm. All the 
immersion solutions were analyzed in a UV-VIS spectrophotometer (microplate 
reader Synergie HT). Previous to the analysis a calibration curve was obtained 
using standard solutions of dextrose (Sigma-Aldrich), allowing the determination 
of the concentration of reducing sugars present in the immersion solutions. 
6. Statistical methods 
6.1 Dixon test (Q-test) 
The Dixon test is an outlier test that informs if the minimum or the maximum 
value of a dataset from the same formulation may be rejected or not. The test is 
based on equation 4 and 5 and was used in the datasets obtained from the 
mechanical analysis. 
 
, for the minimum value Equation 4 
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, for the maximum value Equation 5 
Where the data values are: x1, x2, x3 . . . xn-1, xn. 
Considering a specific probability (in our case 95 %) the Qtabulated is selected from 
the corresponding statistical table. If the Qcalculated<Qtabulated the value was not 
rejected within the given probability and if the Qcalculated>Qtabulated the value was 
rejected within the given probability. 
6.2 Normality test 
All the described statistics can only be applied if the datasets follow a normal 
distribution. Considering this fact, all the datasets were tested for normality using 
the Shapiro-Wilk analysis. This test indicates if the dataset is normally distributed 
at a 95 % probability. Considering the normal distribution, if the p-value was less 
than 0.05, it was considered that the dataset was not significantly drawn from a 
normally distributed population and if the p-value was higher than 0.05 the 
dataset was considered to be significantly drawn from a normally distributed 
population (Figure 10). All the tested datasets were in accordance with the 
normal distribution making it possible to perform a significance test (t-test) [21]. 
 
Figure 10: Scheme of normal distribution (adapted by 
http://www.conferences.utah.edu/ishpssb/publicforum.html). 
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6.3 t-test 
With the t-test it was possible to analyse if the differences between the averages 
of the datasets are significantly or not. The t-test was employed in the analysis of 
the datasets obtained from the mechanical analysis, namely from the 
compressive strength (CS) and modulus (CM) of the cements. A comparison of 
the averages of the datasets is done considering a null hypothesis (mean1-
mean2=0). From the results it was possible to conclude if the differences 
between the averages are significant or not within a 95 % probability. 
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Abstract 
Glass ionomer cements (GICs) are used in dentistry and their application as 
bone cements have been mainly limited by the presence of cytotoxic aluminium 
(Al) in the glass composition. We developed Al-free glasses of general 
composition 0.340SiO2: 0.300ZnO: (0.250-x-y)CaO: xSrO: yMgO: 0.050Na2O: 
0.060P2O5 (x, y = 0.000 or 0.125) and tested them for their cement forming 
ability in the presence of polyacrylic acid (PAA) and water. The influence of the 
type of cations present in the glass (Ca2+, Sr2+ and Mg2+); the PAA molecular 
weight (Mw) and the glass particle size in the cement final properties 
(mechanical behaviour and bioactivity) were evaluated. Enhanced compressive 
strength (25±5 MPa) and modulus (492±17 MPa) was achieved with PAA of 50 
kDa and glass particle sizes between 63-125 µm. The GICs’ in vitro bioactivity 
was tested in simulated body fluid (SBF) and their response analysed by ICP, 
SEM and EDS. Enhanced bioactivity was observed for glass composition 
x=0.125; y=0.000, presenting a surface calcium (Ca)/ phosphorous (P) ratio of 
1.6 (similar to hydroxylapatite) and a surface morphology consistent with a CaP 
coating. Starch was added to the cement formulation x=0.125; y=0.000 (at 
0.050 and 0.250 weight proportions) in order to enhance its biodegradability 
(tested by immersion in phosphate buffer saline in the presence of α-amylase). 
The results obtained from the determination of the reducing sugars in the 
degradation solution indicate that starch only starts to degrade after 8 weeks of 
immersion. Our studies indicate that it is possible to formulate Al-free GIC 
compositions with potential to be used as bone cements. 
 
Keywords: glass ionomer cements, bone cements, mechanical properties, 
bioactive, biodegradable  
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1. Introduction 
Wilson and Kent created the first glass-ionomer cement (GIC), in the early 
1970s [1, 2]. GICs are prepared through the mixing of a glass powder, usually a 
calcium fluoroaluminosilicate, with polyacrylic acid (PAA) and water. The curing 
reactions usually occur in two phases designated as gelation and maturation 
[3]. During gelation the acidic PAA attacks the glass particles at their basic 
sites, promoting the release of cations, e.g. 5-coordinated and 6-coordinated 
aluminium (Al) in the ionic form Al3+, Ca2+, etc., from the glass to the cement 
matrix [4]. This process is followed by the maturation phase that includes the 
leaching of covalently bounded 4-coordinated Al (slower process due to its 
more stable position in the glass structure) and the ionic cross-linking of the 
PAA chains by the leached cations. These two cements curing phases 
generates the final GIC structure - a composite of cross-linked PAA reinforced 
with the reacted glass particles [5]. 
Initial application of this type of cements was in dentistry due to their unique 
properties, namely, its strong adhesion to the hydroxylapatite present in dentin 
and its anti-cariogenic potential [1, 6-8]. Initial drawbacks of conventional GICs 
comprised, e.g. sensitivity to moisture during initial hardening, poor mechanical 
properties, among others. Optimization of their formulations resulted in 
conventional and modified GICs (e.g. resin-modified GICs) with enhanced 
behaviour [9, 10]. GICs continue to be mainly applied in the dentistry field, 
although, some tests have been made to use them as bone cements. These 
attempts revealed to be unsuccessful due to Al cytotoxicity present in the glass 
composition and in the cement matrix [11, 12]. More recently, a series of studies 
[13-15] have been dedicated to eliminate Al from the cement formulation in 
order to avoid its deleterious cytotoxic effect. In fact, Towler and co-workers 
already shown that Al-free glass particles of the ternary system calcium-zinc-
silicates [16] and quaternary system calcium-strontium-zinc-silicates [17, 18] 
possess cement-forming ability. These glass compositions always included low 
calcium/strontium fractions (cumulative values below 0.16) limiting the glass 
reactivity towards the PAA. In this study we hypothesise that: 1) the increase of 
the glass basic sites might increment the glass reactivity inducing an 
enhancement of the GIC mechanical behaviour; 2) the inclusion of higher 
fractions of CaO/SrO/MgO might improve the GIC in vitro bioactivity; 3) it is 
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expectable that the type of divalent cations (group II) included in the glass 
formulations (i.e. Ca2+, Sr2+ and Mg2+) will influence the cement final properties 
(e.g. mechanical behaviour, bioactivity, etc.); and 4) the addition of starch to the 
cement formulation improves the GIC biodegradability. 
 
2. Materials and methods 
2.1 Materials – Glass synthesis 
Glass formulations of general formula 0.340SiO2: 0.300ZnO: (0.250-x-y)CaO: 
xSrO: yMgO: 0.050Na2O: 0.060P2O5 (where x and y = 0.125 or 0.000) were 
prepared by melt quenching using appropriate proportions of glass precursors 
(Table 1). For this purpose, silica (Merck), zinc oxide (Sigma), magnesium oxide 
(Sigma, 98 %), calcium carbonate (Sigma, 99 %), strontium carbonate (Sigma, 
98 %), sodium hidrogenocarbonate (Riedel de-Haen, 99.7 %) and diamonnium 
hidrogenophosphate (Sigma, 98 %) were grounded with a pestle and mortar 
transferred to a crucible and fired to 300 ºC to release ammonia, 650 ºC to allow 
the release of carbon dioxide and to 1300 ºC to produce the melt. 
 
Table 1: Composition of the synthesized glass formulations (mol %). 
Component G1* G2 G3 G4 G5 G6 
SiO2 0.340 0.340 0.340 0.340 0.340 0.340 
ZnO 0.300 0.300 0.300 0.300 0.300 0.300 
MgO 0.250 - - 0.125 - 0.125 
CaO - 0.250 - 0.125 0.125 - 
SrO - - 0.250 - 0.125 0.125 
Na2O 0.050 0.050 0.050 0.050 0.050 0.050 
P2O5 0.060 0.060 0.060 0.060 0.060 0.060 
*G1 – Not possible to produce an homogeneous melt under the used experimental conditions. 
 
Glass blocks were immersed in liquid nitrogen and grounded with a pestle and 
mortar. The glass particles were separated by size using an Analytical Sieve 
Shaker (Retsch AS200) for 5 min at 60 rpm. With this procedure it was possible 
to collect three different fractions (with particle of sizes <63 µm, between 63-125 
µm and between 125-250 µm) for each glass composition. 
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2.2 Cement preparation 
Cements were prepared mixing the glass powder with PAA and water at 
appropriate proportion (55: 21: 24 by mass). PAA of different molecular weights 
(Mws) were tested, namely, 50 kDa (PolySciences); 450 kDa (Sigma-Aldrich) 
and 1250 kDa (Sigma-Aldrich). The cement formulation that presented higher 
mechanical performance was modified to enhance its biodegradability. To this 
purpose it was added corn starch (Sigma) to formulations in weight percentages 
of 5 % and 25 %. All the cement pastes (immediately after mixing) were shaped 
in a Teflon mould to produce cylindrical specimens of 6 mm diameter and 11 
mm height. 
 
2.3 Glass and cement characterization 
2.3.1 X-Ray Diffraction 
The crystalline/amorphous state of the synthesized glass formulations was 
evaluated by x-ray powder diffraction (XRD). Diffractograms were collected on a 
Bruker D8 Discover, operating with Cu Kα radiation, in θ/2θ mode, between 6° 
and 70°, with a step increment of 0.04° and an acqu isition time of 1 s per step. 
2.3.2 Fourier Transform Infrared spectroscopy 
 The Fourier Transform Infrared (FTIR) spectra of the glasses and cements 
were collected using KBr (Sigma, 99%+) pellets on a Shimadzu IR-Prestige 21 
spectrometer under transmittance mode, between 4400-400 cm-1, using a 
resolution of 4 cm-1 and 32 scans. 
2.3.3 Mechanical testing 
 The compressive strength (CS) and modulus (CM) of the cements were 
evaluated. The developed cement formulations were mechanically tested under 
compression loading on an Instron 5540 (Instron, USA) using a 1 kN load cell 
and 2 mm/min of crosshead speed. Six cylindrical specimens of each 
formulation were tested 1 day after preparation. The specimen compressive 
strength (CS) was calculated according to equation 1: 
 
(1) 
where ρ is the maximum applied load (N) and d is the diameter of the sample 
(mm). 
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The compressive modulus (CM) was calculated as the initial slope (elastic 
regime) of the stress-strain curves of each cement specimen. 
Averages were calculated for the CS and CM of each cement formulation 
and the normality of the data distribution was confirmed using the Shapiro-Wilk 
test. Significant differences (95 % probability) between the cement formulations 
were calculated using the t-test. 
 
2.4 Bioactivity tests 
2.4.1 In vitro bioactivity 
 Cement formulations were immersed in Simulated Body Fluid (SBF, prepared 
according to a previously established procedure [14]) during 7 and 14 days. At 
these specific time points, the specimens were collected from the solutions. The 
calcium (Ca) and phosphorous (P) concentrations of the initial SBF and 
immersion solutions were analyzed by Inductive Coupled Plasma – Optical 
Emission Spectroscopy (ICP-OES) and the elemental composition and 
morphology of the immersed and non-immersed cement surfaces were 
evaluated by Energy Dispersive X-ray spectroscopy (EDS) and Scanning 
Electron Microscopy (SEM). 
2.4.2 Inductive coupled plasma – optical emission spectroscopy 
ICP-OES was used to determine the Ca and P concentrations in the SBF 
solutions before and after the immersion of the developed cements. The 
samples’ absorption at specific wavelengths ( λ =422.67 nm for Ca and 
λ =213.62 nm for P) was measured and the Ca and P concentrations were 
determined from the calibration curves previously obtained with standard 
solutions (Alfa Aesar). 
2.4.3 Energy-Dispersive x-ray Spectroscopy 
 The Energy-Dispersive x-ray spectroscopy (EDS) was used to quantify the 
Ca and P present in the surface of the cements. A Link eXL-II Oxford 
Spectroscope was used at an energy of 7.0 keV and the samples were carbon 
coated to improve their conductivity. 
2.4.4 Scanning Electron Microscopy 
 Micrographs of the cement samples were collected on a Leica Cambridge 
S360 microscope using a beam energy of 15.0 kV and a working distance (WD) 
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of 19 mm. All the samples were previously coated with gold and the morphology 
of the CaP layers was verified after 7 and 14 days of immersion in SBF. 
 
2.5 Water uptake and weigh loss 
Cement samples (prepared 24 h before testing) were immersed in Phosphate 
Buffer Saline (PBS) solution at a ratio of 1:15 (sample mass: PBS volume) and 
inserted in a shaking water bath maintained at 37 ºC and 60 rpm. Cement 
samples were collected at various time points (1, 2, 4, 8 and 12 weeks). They 
were washed with distilled water, the excess water present in the surface was 
dried with paper and the samples were immediately weighted. The water uptake 
(WU) was calculated using the equation 2. 
 
 
(2) 
 
where, mtp is the wet mass at the specific time point and mf is the mass of 
cement after drying at 37 ºC to constant weight. 
The weight loss (WL) was calculated during the water uptake (WU) tests. In 
the WL case, the cements were removed from the PBS solution at the same 
time intervals as the ones used for the WU (1, 2, 4, 8 and 12 weeks) and were 
dried into the oven, at 37 ºC, until constant weight. The percentage of WL was 
calculated using the equation 3. 
 
 
(3) 
 
where, mf is the mass of the dried cement after its immersion in PBS and mi is 
the mass of the cement before immersion in PBS. 
 
2.6 Degradation tests  
The degradation of the starch-containing cements was tested in the presence 
of a starch-specific enzyme, α-amylase. This enzyme is known to hydrolyse the 
α-1,4-glycosidic linkages of polysaccharides (e.g. starch) to monosaccharides, 
such as, maltose and dextrins. 
Cement degradation was promoted by immersion of specimens in an enzyme 
containing solution (150 U/L) for different time periods, 0, 1, 2, 4, 8, and 12 
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weeks. At the specific time points, the solutions were analysed for the presence 
of reducing sugars. Their concentration was determined by the dinitrosalicylic 
acid (DNS) method. The 3,5-dinitrosalicylic acid is converted to 3-amino-5-
nitrosalicylic acid in alkaline conditions. This last compound (3-amino-5-
nitrosalicylic acid) forms a complex with the reducing sugars, which presents an 
absorption peak at 540 nm. All the immersion solutions were analyzed in a UV-
VIS spectrophotometer (microplate reader Synergie HT). Previous to the 
analysis a calibration curve was obtained using standard solutions of dextrose 
(Sigma-Aldrich, nd), allowing the determination of the concentration of reducing 
sugars present in the immersion solutions. 
 
2.7 Micro-Computed Tomography 
The cement samples were analysed by micro-Computed Tomography (micro-
CT) in order to determine the polymer, glass and pore spatial distributions and 
volume percentages. The collection of images was performed in a micro-CT 
Skyscan 1072 (Skyscan, Belgium) operating with a voltage of 104 kV and with a 
current of 96 µA. Upon image acquisition the noise was reduced using nRecon 
software. Afterwards, 200 sliced images were obtained using the CT-An 
program. These images were used to produce a 3D reconstruction with the 
same program (CT-An). Manipulating the image with a threshold of 40 to 80 for 
the glass and 80 to 140 for the polymer it was possible to separate the 
contribution of these components to the cement volume, as well as the free 
pore volume. 
 
3. Results and discussion 
3.1 Glass characterization 
3.1.1 X-Ray Diffraction 
The XRD diffractograms of all the synthesised glass compositions presents 
the predominance of the amorphous state with a low contribution of crystalline 
phases only in the cases of samples G4 and G6 (see Figure 1). 
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Figure 1: X-ray powder patterns of the synthesised glass formulations. 
 
3.2 Cement characterization 
3.2.1. Chemical characterization 
 FTIR spectra of the cement samples (cured during 24 h) were used to 
characterize their curing reactions and chemical structure. As an example, 
Figure 2 presents the FTIR spectra of PAA, glass G5 and cement C5. 
2000 1800 1600 1400 1200 1000 800
C5
PAA
Wavenumber (cm-1)
G5
 
 
 
Figure 2: FTIR spectra of PAA, glass G5 and cement C5 
  
It is known that the cement curing reactions comprises an acid attack 
promoted by the PAA carboxylic acids on the surface layer of the glass particles 
that partially leaches its cations to the cement matrix. These leached cations 
crosslink the polymeric chains (at the COO- groups from the PAA) through the 
formation of ionic linkages [3]. In fact, the PAA, glass and cement FTIR spectra 
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(Figure 2) are consistent with this reaction model. Upon acid attack the PAA 
COOH stretching at 1750 cm-1 (observed before the curing reaction) is shifted 
to two peaks (symmetric and asymmetric stretching between 1640 cm-1 and 
1550 cm-1) of its ionized form (COO-). 
 
3.2.2 Mechanical testing 
a) Influence of glass particle size and PAA molecular weight on the cement 
mechanical behaviour. 
 The influence of the glass particle size and the PAA molecular weight (Mw) 
on the mechanical behaviour of the cement (CS and CM) was also studied. To 
this purpose, three glass powder fractions (using G5) with different particle size 
distributions were obtained by sieving (i.e. <63 µm; 63 µm<x<125 µm and 125 
µm<x<250 µm) and three PAA samples of different Mws (50 kDa, 450 kDa and 
1250 kDa) were tested. The CS and CM values obtained with the cements 
prepared with the sieved glass powders and the PAA samples of different Mw 
are presented in Figure 3.  
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Figure 3: Compressive modulus (CM) and compressive strength (CS) of the cements 
prepared with the different particle sizes of glass powder and PAA Mws. 
 
Higher CS and CM values were obtained using PAA of 50 kDa and glass 
particle sizes between 63 µm and 125 µm. In all the cases, when the glass 
particle size distribution or PAA Mw deviated from these optimal conditions, CM 
decreased significantly. In the case of the CS, not always it was observed a 
significant decrease, although, it was clear that the above mentioned optimal 
conditions yielded a cement formulation with enhanced CS [19, 20]. 
It was observed that a proper mixing of the cement paste would necessitate 
more water when the glass particle sizes are <63 µm. Although, other reports 
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[21] suggest that lower particle sizes would be beneficial for the cement 
mechanical properties. From our results it is possible to conclude that this 
relation is not universal and that the optimal glass particle sizes might vary with 
the glass composition. In fact, it is reasonable to assume that the higher the 
reactivity of the glass particles the higher should be the glass particle sizes (and 
consequently lower the surface area). If low particle sizes are used on glasses 
with high reactivity towards PAA their reaction is so fast that it is not possible to 
produce an homogeneous cement paste. In these cases the cement’s working 
time is too short to allow its application in the cementation of bone and to yield 
enhanced mechanical performance. 
 
b) Influence of the composition of each cement in the mechanical behaviour 
 In Figure 4 is presented the CM and CS obtained for the cement 
formulations prepared using the synthesised glasses (with particle size between 
63 and 125 µm), PAA (50 kDa) and water.  
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Figure 4: Compressive modulus (CM) and compressive strength (CS) of the developed 
cements. 
 
Analysing the results obtained for the CM values it is clear the existence of 
two groups of formulations: group 1 composed by C4 and C6 that present lower 
CM; and group 2 composed by C2, C3 and C5 that exhibit higher CM. No 
significant differences were observed within each group, although, significant 
variations (95 % probability) were observed between the samples of the two 
groups. It is interesting to notice that lower CM is obtained for the cements 
prepared with glasses that presented MgO in the composition. 
The mechanical analysis was complemented with the determination of the 
CS of the same cement formulations. From the three cements that presented 
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higher CM (C2, C3 and C5) the only one that presented a significantly higher 
mechanical resistance was C5. Overall, it presented a CM of 492±17 MPa and 
a CS of 25±5 MPa. 
 
3.2.3 In vitro bioactivity 
 The ability of the cements to promote the formation of calcium phosphate 
(CaP) layers on their surface (in the presence of SBF) was used as a measure 
of their in vitro bioactivity. At a first stage cement samples were immersed in 
SBF for 7 and 14 days. ICP-OES was used to monitor the Ca and P 
concentration in the SBF solution before and after the cement immersion. Table 
2 summarizes the Ca and P concentrations as percentage of the concentration 
in the original SBF. 
 
Table 2: Ca and P concentrations in the SBF solutions after 7 and 14 days of 
immersion of GIC samples. Values are presented as percentage of the concentrations 
present in the original SBF, used as reference. 
 
 
7 days 14 days 
Samples % Ca % P % Ca % P 
SBF 100.00 100.00 100.00 100.00 
C2 63.04 62.96 64.13 59.26 
C3 21.74 51.85 21.74 51.85 
C4 52.17 40.74 57.61 40.74 
C5 42.39 55.56 40.22 48.15 
C6 18.48 51.85 20.65 59.26 
 
 The results clearly show a decrease of the Ca and P concentrations in the 
SBF for all the cement samples. The larger variations on the Ca were observed 
for C3 and C6, although, these are not accompanied by the P concentrations. In 
fact, the reduction in the P (concentrations between 40 % and 63 %) are 
levelled in all the cement formulations. In this case it is not noticed any specific 
trends. 
 ICP-OES of the immersion solution is an indirect method to determine the 
ability of the cements to produce CaP. The direct analysis of the elemental 
composition of the surfaces of the cements (after immersion in SBF for 7 and 14 
days) was done using EDS (Figure 5).  
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Figure 5: EDS spectra the surface of cement C5 immersed in SBF for 7 and 14 days 
(spectrum of non-immersed cement shown as reference – 0 days). 
 
From the EDS spectra it was possible to collect the Ca and P concentrations 
in the cement surfaces (Table 3). It is known that biomaterials with high 
bioactivity present thicker CaP layers and these layers present the 
hydroxyapatite crystalline form. It is also known that the Ca/P ratio for 
hydroxyapatite is, approximately, 1.62 [22, 23]. In this perspective, the closer 
the Ca/P ratio is to the hydroxyapatite ratio the higher is the bioactivity of the 
cement. Under this assumption, the cement sample C5 presented Ca/P ratios of 
1.8 and 1.6 at 7 and 14 days of immersion in SBF, respectively. From all the 
tested formulations, the C5 Ca/P values were the closest to hydroxyapatite, 
being considered as the one that presented highest bioactivity. 
 
Table 3: Ca/P ratio of all cements after 7 and 14 days. 
Cement 
7 days 14 days 
Ca P Ca/P Ca P Ca/P 
C2 0.83 1.20 0.70 2.30 1.97 1.17 
C3 1.20 1.24 0.97 1.88 1.31 1.43 
C4 1.48 0.99 1.49 0.79 1.14 0.70 
C5 1.26 0.70 1.79 2.19 1.42 1.55 
C6 0.53 0.74 0.71 0.45 0.58 0.77 
Ca/P of hydroxyapatite 1.62. 
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 In order to complement the analysis, SEM was used to monitor the 
morphology of the CaP layers (cement C5 presented in Figure 6 as an 
example). 
 
Figure 6: SEM micrographs of cement C5 before and after immersion in SBF for 7 and 
14 days. 
 
 SEM analysis demonstrated the change in the cement morphology upon SBF 
immersion. Before immersion the cement surface is smooth without CaP 
crystals, while after 7 and 14 days of immersion it is possible to observe the 
formation of CaP layers that in some cases present the cauliflower form, 
characteristic of hydroxyapatite. 
 Considering the in vitro bioactivity and mechanical testing results it was clear 
that cement C5 exhibited properties that best match their use as bone cement. 
In this perspective, this composition was selected for subsequent analysis and 
testing. 
 
3.2.4 3D distribution of glass, PAA and porosity of C5 cement 
 Micro-CT was used to obtain the spatial distribution of the glass particles, 
PAA and porosity of the cement sample that exhibited higher mechanical 
performance and bioactivity (C5). 
 The analysis of the C5 micrographs (Figure 8) indicates a higher 
predominance of PAA in the surface of the cement than in the bulk. This is 
assigned to the moulding process executed for all the formulations before the 
analysis. Additionally, using the micrographs it was possible to determine the 
porosity of the cement samples. In the case of cement C5 it was calculated a 
porosity of, approximately, 35 % in volume.  
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3.2.5 Water uptake and weight loss 
The cement that presented higher mechanical performance and bioactivity 
(C5) was again chosen to study the water uptake and weight loss of this type of 
cement formulations. In this case, C5 presented an initial water uptake of 22 % 
that stabilised 1 week after immersion, reaching a plateau between 22 % and 
25 % during all the subsequent time period (12 weeks) (Figure 9 and Figure 
10). 
 
3.3 Addition of starch to the cement formulation  
3.3.1 Mechanical testing 
Cement sample C5 was prepared with two different percentages of starch (5 
% and 25 %). As expected the incorporation of starch as filler in the cement 
formulations produced a decrease of its mechanical performance (see Figure 
7). 
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Figure 7: Compressive strength (CS) and compressive modulus (CM) for the cements 
as a function of the percentage of starch in the formulations. 
 
It is always observed a significant decrease on the CS and CM when starch 
is included in the formulation. In the case of CM this decrease is limited to, 
approximately, 20 % when 5 % of starch is added, although, when higher 
percentages of starch are used the reduction of CM is higher than 65 %. CS is 
more sensitive to the inclusion of starch. In fact, the addition of 5 % of starch 
produced a decrease of, approximately, 50 % of the CS of the initial cement 
formulation. 
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3.3.2 3D distribution of the glass, polymers and porosity on the starch-
containing cements 
The 3D micrograph of the C5 cement with 0 %, 5 % and 25 % of starch is 
presented in Figure 8. It is clearly noticed a reduction of the PAA domains 
(lighter regions) in the surface of the cement with the increase of starch content. 
In fact, it was observed an increase of viscosity of the cement paste with the 
addition of starch. Under these conditions it is expectable a lower mobility of the 
PAA during the moulding process, limiting its diffusion to the surface of the 
cement. 
C5 without starch 
C5 with 5% of starch 
   C5 with 25% of starch 
 
Figure 8: Micro-CT bidimensional image and 3D image of C5 cement without starch 
and with 5 % and 25 % of starch. 
 
With the acquired micrographs it was also possible to determine the porosity 
of the cement samples. The inclusion of starch into the cement formulation 
produced an increase of porosity from, approximately, 35 %  to 43 %. It is clear 
that the packing of the starch particles within the cement structure induces the 
appearance of a significant free-volume that is the responsible for the increment 
of the cement porosity. When the starch percentage was increased from 5 % to 
25 % no significant variations in the porosity was observed. In fact, the porosity 
is maintained within the 41 % and 42 % range. 
 
3.3.3 Water uptake and weight loss 
 The WU and WL of the C5 cement with 0 %, 5 % and 25 % of starch was 
determined through the immersion of the cement samples in PBS (at the 
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physiological pH, 7.4) during different time periods (up to 12 weeks). The 
solution pH value was monitored throughout the experiment. It was observed a 
reduction of the pH from the initial 7.4 to 7.0. This result was attributed to the 
partial solubilisation of the PAA present in the cement formulations. 
 In relation to the WU all the cements presented a similar general trend. It is 
observed an initial uptake during the first week (between 20 % and 37 %) that is 
maintained throughout the timeframe of the experiment (Figure 9). The inclusion 
of starch in the cement composition increased the hydrophilicity of the cements 
and their WU values change from, approximately, 25 % (C5 without starch) to 
28 % (C5+5 % starch) and 35 % (C5+25 % starch). The enzymatic environment 
did not induce any observable differences in the WU of the cements when 
compared to the cements immersed in PBS without α-amylase. 
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Figure 9: Water uptake (WU) of the cements under PBS (a) and PBS + α-amylase (b) 
during 12 weeks. 
 
The WLs of the cement C5 with and without the addition of starch are similar 
(Figure 10). In fact it is observed an initial WL between 10 % and 16 % during 
the first week of experiment that is maintained throughout all the timeframe of 
the experiment. Comparing the WL values after 12 weeks of immersion, the 
observable differences between the samples are not significant (between 11 % 
and 13 % of WL). When the same formulations were immersed in PBS solution 
in the presence of α-amylase it was expectable to observe a higher decrease of 
WLs in the starch containing formulations. Although, the results indicate that the 
enzymatic medium has an inhibitory effect on the processes that are 
responsible for the WL of the GICs. 
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Figure 10: Weight loss (WL) of the cements under PBS (a) and PBS + α-amylase (b) 
during 12 weeks. 
 
In fact, it is clear from our results that the WL is reduced to approximately half 
when enzymatic medium is used. Under these not expectable results, it is 
relevant to evaluate if the starch is actually degrading into reducing sugars or 
not. 
3.3.4 Degradation tests 
Starch was added to cement C5 in order to enhance the cement 
degradability, although, WL studies under enzymatic medium showed that the 
cement WLs were diminished. In this perspective the enzyme activity and starch 
degradation rate was monitored through the measurement of the concentration 
of reducing sugars released from the cements into the PBS. 
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Figure 11: Concentration of reducing sugars in the cements (with 5% and 25% of 
starch) after immersion in PBS during 12 weeks. 
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The concentration of the reducing sugars increased as a function of time after 
the 8 and 12 weeks and no significant differences were observed for the 
cements in the first three time points (1, 2 and 4 weeks) (see figure 11). 
Apparently, the starch particles are only in contact with the enzymatic medium 
after the eighth week of immersion. Until this time point it they appear to be 
entrapped in the GIC structure without any connection with the immersion 
solution. 
Considering the increasing of the concentration of reducing sugars in the 
enzymatic medium (after the 8th week of immersion) there is a clear indication 
that the addition of starch to the GIC formulations induces an enhanced 
biodegradability at a larger timeframe than expectable. 
 
4. Conclusions 
 Our results demonstrate that it was possible to prepare Al-free glass-ionomer 
cement formulations using glasses of general formula 0.340SiO2: 0.300ZnO: 
(0.250-x-y)CaO: xSrO: yMgO: 0.050Na2O: 0.060P2O5 (where x and y = 0.000 or 
0.125). The inclusion of MgO revealed not appropriate for the achievement of 
cement with enhanced mechanical performance and bioactivity. Although, the 
combination of SrO and CaO (G5, x= 0.125; y= 0.000) produced a glass 
composition that generated cements with enhanced mechanical performance 
(CS=25±5 MPa and CM=492±17 MPa) and bioactivity (Ca/P= 1.6), with limited 
WU (approximately, 20 %) and WL (approximately, 13 %).  
The optimized C5 cement formulation presented porosities in the range of 35 
% that could be increased to 43 % with the inclusion of starch in the cement 
formulation. Moreover, the presence of reducing sugars in the enzymatic 
degradation solution after 8 weeks of testing indicates the existence of 
improved biodegradability at a longer timeframe than expected. 
Our work demonstrates that it is possible to design Al-free glass-ionomer 
cement formulations that exhibit suitable mechanical performance and 
bioactivity. The elimination of the Al from the glass generates cement 
formulations suitable to be used as bone cements. The collected data is also 
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consistent with the possibility to develop formulations with improved 
biodegradability if starch (up to 25 %) is added to the cement formulation. 
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Aluminium-free GICs were developed through the combination of PAA, 
water and glass formulations of general formula 0.340SiO2 : 0.300ZnO : (0.250-
x-y)CaO : xSrO : yMgO : 0.050Na2O : 0.060P2O5 (x, y = 0.125 or 0.000). Their 
mechanical performance was evaluated yielding compressive strengths (CS) 
and moduli (CM) between 11 MPa - 25 MPa and 227 MPa – 492 MPa, 
respectively. Highest results (CS = 25 MPa; CM = 492 MPa) were obtained with 
glass composition 0.340SiO2 : 0.300ZnO : 0.125CaO : 0.125SrO : 0.050Na2O : 
0.060P2O5, a glass particle size between 63 µm<x<125 µm and a PAA Mw of 50 
kDa. 
The PAA and glass distribution within the GIC samples was studied by micro-
CT, revealing that the PAA is mainly in the outer surface of the GICs while the 
reacted glass particles are homogeneous distributed throughout its bulk. This 
PAA migration to the surface of the samples may be a consequence of the 
pressures promoted by the moulding process. Additionally, this observation is 
also consistent with the higher mobility of the PAA (compared to the glass 
particles) within the cement paste before final curing. 
The in vitro bioactivity of the developed GICs was evaluated by a series of 
techniques (ICP of the immersion SBF solutions and EDS/SEM of the cement 
surface before and after immersion). In all the cases they demonstrated the 
GICs’ ability to promote the formation of a calcium phosphate layer at their 
surface. 
Finally, in an attempt to impart biodegradability to the GICs, they were 
formulated with the addition of starch at weight percentages of 5% and 25%. 
The porosity of the developed starch containing GICs (determined by micro-CT) 
was in the range of 35% to 43%. Additionally, when no enzyme was used in the 
immersion solutions the samples’ WL were similar to the control sample (0% 
starch), although, unexpectedly, when an enzymatic medium was used a lower 
WL was recorded. A possible explanation for the lower WL observed with the 
samples subject to enzymatic medium is related with the inhibition of the 
processes that induce the WL of the GICs (e.g. 0% starch). These processes 
might comprise the partial solubilisation of PAA and leaching of cations from the 
glass particles and cement matrix to the immersion solution. 
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Under these circumstances it was not possible to conclude about the starch 
containing GICs degradation from the observed WLs. In this perspective, the 
determination of the concentration of reducing sugars was executed and 
confirmed their increasing presence after 8 weeks of immersion. These results 
provided evidence that the starch degraded at a longer timeframe than 
expectable. 
In general, the results showed that it is possible to formulate aluminium-free 
GICs with mechanical behaviour suitable to be used as bone cements in non 
load-bearing sites. The developed GICs presented significant bioactivity giving 
a good indication on their suitability for in vitro and/or in vivo testing. The 
inclusion of starch to the cement formulations imparted degradability in the 
GICs (supported by the occurrence of reducing sugars in the degradation 
enzymatic solution), although, the reduction of the WL when enzymatic medium 
was used requires further evaluation to understand the mechanisms involved in 
the degradation/solubilisation processes. 
The work executed under this thesis resulted in promising perspectives for the 
biological testing of the developed GIC formulations in vitro and/or in vivo. 
Under this perspective it is relevant to project as future work the evaluation of 
their cytotoxicity. Initial in vitro procedure should comprise indirect contact 
method [1-3]. Afterwards, and still under in vitro testing, it is highly relevant to 
evaluate the suitability of the developed bone cements within similar conditions 
than the ones that it will face on its application site. For this purpose, it is 
relevant to evaluate the behavior of osteoblasts (one of the main type of cells 
responsible for osteogenesis) in the presence of cement specimens. 
The outcome of the in vitro biological testing is determinant to define the 
following research steps. In this sense, if positive results are obtained from the 
in vitro testing, it is relevant to initiate in vivo testing; if negative results are 
obtained, the research should come back to the formulation stage with 
optimization of the glass composition or the polymeric part. 
Another section that is opened to optimization is the PAA component. In fact, it 
is known that its high acidity induces pH reduction in the surrounding tissue, 
promoting inflammatory response. Its substitution by different types of polymeric 
acids is a valuable alternative that requires evaluation. Some of these 
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alternatives can be polysaccharide-based due to their known biocompatibility 
and in some cases bioactivity. Examples of these polymers are hyaluronic acid 
or carboxymethyl chitosan [4, 5]. 
The analysis of the reducing sugars, present in the degradation solution of the 
starch containing GICs, revealed that starch degradation only starts after the 8th 
week of degradation (within a 12 weeks study). In this perspective it is also 
relevant to test the degradability of the same starch containing GICs at a longer 
time frame. 
Finally, the application of bone cements within the clinical domain requires 
strategies that enable versatility and simplicity of application to the clinician. In 
this perspective, it is relevant to evaluate the suitability of the developed 
formulations as injectable bone cement (one of the most used application 
systems). Under this approach, the optimization of the GIC formulation might be 
required in order to better control their setting time (the time that ranges from 
the start of mixing and the lost of cement moldability) [6-12]. 
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